Innocan Pharma publishes 2025 MD&A report, flags US$36M accumulated deficit

  • Innocan published MD&A report for fiscal 2025, outlining plan to advance LPT-CBD long-acting synthetic CBD injection toward first-in-human testing.
  • Scale-up work for LPT-CBD is expected to take about one year, followed by GLP single-injection safety study with final reporting expected in 6-8 months.
  • IND submission is planned once safety data are available, with Phase 1a start targeted 30 days post-submission if no clinical hold is issued.
  • Animal-health program targets INAD filing during 2026 for chronic pain in dogs, supported by continued FDA-CVM sponsor fee waiver for LPT-CBD.
  • Consumer wellness segment remained revenue base, with revenue down to USD 27 million from USD 29 million; cash rose to USD 6.7 million from USD 5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.